Literature DB >> 21719117

Evolutionarily conserved T-cell epitopes on FIV for designing an HIV/AIDS vaccine.

J R Abbott1, M P Sanou, J K Coleman, J K Yamamoto.   

Abstract

This review will discuss the current state of the human HIV-1 vaccine trials including the safety consideration of vaccine composition and difficulties in determining and defining protective immunity and epitopes to HIV-1. Vaccines in animal models of lentivirus infection are compared. In particular, the findings from the prototype FIV vaccine and the HIV-1 protein immunizations studies in cats are discussed, as well as the resulting research regarding a potential HIV-1 vaccine design based on evolutionarily conserved T-cell epitopes.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21719117      PMCID： PMC4461867          DOI： 10.1016/j.vetimm.2011.06.019

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN： 0165-2427            Impact factor:   2.046


  36 in total

1.  RV144: old vs. new.

Authors:  David B Weiner
Journal:  Hum Vaccin       Date:  2010-02-18

2.  HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection.

Authors:  James K Coleman; Ruiyu Pu; Marcus Martin; Eiji Sato; Janet K Yamamoto
Journal:  AIDS       Date:  2005-09-23       Impact factor: 4.177

3.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors:  Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal:  J Infect Dis       Date:  2006-11-03       Impact factor: 5.226

4.  Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV.

Authors:  J J Kim; K A Simbiri; J I Sin; K Dang; J Oh; T Dentchev; D Lee; L K Nottingham; A A Chalian; D McCallus; R Ciccarelli; M G Agadjanyan; D B Weiner
Journal:  J Interferon Cytokine Res       Date:  1999-01       Impact factor: 2.607

Review 5.  Feline immunodeficiency virus pathogenesis and development of a dual-subtype feline-immunodeficiency-virus vaccine.

Authors:  Janet K Yamamoto; Ruiyu Pu; Eiji Sato; Tsutomu Hohdatsu
Journal:  AIDS       Date:  2007-03-12       Impact factor: 4.177

Review 6.  HIV-1 vaccine development after STEP.

Authors:  Dan H Barouch; Bette Korber
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

7.  Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.

Authors:  Punnee Pitisuttithum; Sorachai Nitayaphan; Prasert Thongcharoen; Chirasak Khamboonruang; Jerome Kim; Mark de Souza; Thippawan Chuenchitra; Robin P Garner; Darawan Thapinta; Victoria Polonis; Silvia Ratto-Kim; Penprapa Chanbancherd; Joseph Chiu; Deborah L Birx; Anne-Marie Duliege; John G McNeil; Arthur E Brown
Journal:  J Infect Dis       Date:  2003-07-03       Impact factor: 5.226

Review 8.  Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses?

Authors:  Joel N Blankson
Journal:  Antiviral Res       Date:  2009-09-04       Impact factor: 5.970

9.  Peptide mapping of feline immunodeficiency virus by IFN-gamma ELISPOT.

Authors:  Gregg A Dean; Alora LaVoy; Mary Jo Burkhard
Journal:  Vet Immunol Immunopathol       Date:  2004-07       Impact factor: 2.046

10.  Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens.

Authors:  Nia Tatsis; Marcio O Lasaro; Shih-Wen Lin; Larissa H Haut; Zhi Q Xiang; Dongming Zhou; Lauren Dimenna; Hua Li; Ang Bian; Sarah Abdulla; Yan Li; Wynetta Giles-Davis; Jessica Engram; Sarah J Ratcliffe; Guido Silvestri; Hildegund C Ertl; Michael R Betts
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422
View more
  4 in total

1.  Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects.

Authors:  Missa P Sanou; Shannon R Roff; Antony Mennella; John W Sleasman; Mobeen H Rathore; Janet K Yamamoto; Jay A Levy
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

2.  Major Histocompatibility Complex Class I (FLA-E*01801) Molecular Structure in Domestic Cats Demonstrates Species-Specific Characteristics in Presenting Viral Antigen Peptides.

Authors:  Ruiying Liang; Yaping Sun; Yanjie Liu; Junya Wang; Yanan Wu; Zibin Li; Lizhen Ma; Nan Zhang; Lijie Zhang; Xiaohui Wei; Zehui Qu; Nianzhi Zhang; Chun Xia
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

Review 3.  Lessons Learned in Developing a Commercial FIV Vaccine: The Immunity Required for an Effective HIV-1 Vaccine.

Authors:  Bikash Sahay; Janet K Yamamoto
Journal:  Viruses       Date:  2018-05-22       Impact factor: 5.048

4.  Immunogenicity and Efficacy of a Novel Multi-Antigenic Peptide Vaccine Based on Cross-Reactivity between Feline and Human Immunodeficiency Viruses.

Authors:  Bikash Sahay; Alek M Aranyos; Meerambika Mishra; Andrew C McAvoy; Marcus M Martin; Riuyu Pu; Sayaka Shiomitsu; Keijiro Shiomitsu; Michael J Dark; Missa P Sanou; Shannon R Roff; Mobeen H Rathore; Janet K Yamamoto
Journal:  Viruses       Date:  2019-02-03       Impact factor: 5.048
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.